San Francisco-based Foresite Capital, a leading investment firm in healthcare and life sciences, has closed its sixth fund with $900 million in capital commitments. This significant milestone underscores the firm’s commitment to advancing innovative technologies within the healthcare and life sciences sectors. Fund VI has attracted a diverse group of investors, including university endowments, charitable foundations, medical institutions, pension funds, insurance companies, private banks, and family offices globally, reflecting broad confidence in Foresite Capital’s investment strategy.
With the new fund, Foresite Capital will focus on three key areas: precision therapeutics, life science infrastructure, and healthcare delivery. Precision therapeutics aims to develop treatments tailored to individual patient needs for better efficacy, while life science infrastructure investments will support companies providing critical services within the industry. Healthcare delivery investments will target more efficient and accessible healthcare models.
Founded in 2011, Foresite Capital manages over $3.5 billion in assets and operates from the San Francisco Bay Area, Los Angeles, and New York City. The firm has a strong track record, with over 47 IPOs, 28 mergers and acquisitions, and 58 FDA-approved drugs, all achieved through a data and science-driven investment approach. Fund VI’s portfolio includes promising companies like Alumis, CG Oncology, Latigo, RayThera, Evonetix, and Xaira Therapeutics.
Jim Tananbaum, founder and CEO of Foresite Capital, emphasized that advances in biology, genomics, and artificial intelligence are driving biotech innovation, making this an optimal time for investment. Hadi Tabbaa, Managing Director and Head of Investor Relations and Business Development, expressed gratitude for the support from both long-standing partners and new investors, highlighting the firm’s mission to support entrepreneurs tackling significant challenges in the healthcare system and improving patient lives.